• Sulforaphane, PM2.5, and COPD: Mechanistic Evidence

  2026-09-03

  A 2026 Phytotherapy Research study investigated how sulforaphane protects against PM2.5-induced COPD-like injury by activating Nrf2 and suppressing EGFR/PI3K/AKT signaling. Its integrated rat, cell, network pharmacology, docking, and EGFR-silencing design connects antioxidant and growth-factor pathways while highlighting the limits of translating preclinical findings to human COPD.

• T0070907: A PPARγ Antagonist Workflow

  2026-09-03

  T0070907 is a covalent, high-affinity PPARγ antagonist for separating receptor-dependent transcription from downstream cellular effects. This guide translates its nanomolar pharmacology into workflows for adipogenesis, RXRα/PPARγ pathway studies, foam-cell inflammation, and cancer cell-cycle research.

• NLRP10, Keratinocyte Survival, and AD Barrier Function

  2026-09-02

  This 2024 Cell Death & Disease study identifies NLRP10 as a regulator of epidermal homeostasis rather than merely an inflammation-associated NLRP family protein. Using human atopic dermatitis samples and an air-lift human skin equivalent, the authors connect NLRP10 to caspase-8-dependent keratinocyte survival, p63 stabilization, epidermal differentiation, and barrier integrity.

• Anti-RPS6 Antibody for Translational Assays

  2026-09-02

  The Anti-RPS6 antibody MA4974 provides a validated route to measure total RPS6 across signaling, ribosome biogenesis, and PDAC-related experiments. This guide explains how to interpret RPS6 measurements alongside the LRRC8A–Caveolin-1 mechanism without confusing protein abundance with pathway activation.

• SAR131675 in VEGFR-3 Pathway Assays

  2026-09-01

  SAR131675 is a selective VEGFR-3 inhibitor for dissecting lymphangiogenesis, endothelial migration, and tumor biology. This guide connects its kinase and cell-based evidence with assay-design lessons from nicotine-associated chronic kidney disease research.

• Tomivosertib in Acute Myeloid Leukemia: Study Insights

  2026-08-31

  Suarez and colleagues evaluated Tomivosertib as a highly selective MNK1/2 inhibitor in acute myeloid leukemia (AML), linking suppression of eIF4E Ser209 phosphorylation with reduced leukemic-cell viability and progenitor colony formation. The study also identified synergy with Venetoclax and used proteomic and interaction studies to refine understanding of MNK-associated complexes.

• Z-LEHD-FMK in Caspase-9 Apoptosis Assays

  2026-08-31

  Z-LEHD-FMK is an irreversible caspase-9 inhibitor for separating mitochondria-mediated apoptosis from downstream cell-death signals. This guide connects practical apoptosis assay design with caspase activity measurement, TRAIL models, and translational neuroprotection workflows while emphasizing formulation, controls, and interpretation.

• HNRNPU K181 Lactylation Reprograms Cervical Cancer

  2026-08-30

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a lactate-responsive mechanism that stabilizes PHGDH mRNA, activates serine biosynthesis, and promotes cervical cancer growth. Its findings connect a non-histone post-translational modification with RNA regulation and suggest experimental strategies for testing metabolic and protein-stability mechanisms.

• Otilonium Bromide: Antimuscarinic Research Guide

  2026-08-29

  Otilonium Bromide is a quaternary ammonium antimuscarinic agent for in vitro studies of cholinergic signaling and smooth muscle pharmacology. Its defined molecular weight, supplier-reported solubility, and available DMSO stock format support controlled neuroscience receptor modulation and gastrointestinal motility disorder model workflows, but the cited SARS-CoV-2 NSP15 study does not establish antiviral activity for this compound.

• Tranexamic Acid: Designing Better Clot Assays

  2026-08-29

  Tranexamic Acid is an antifibrinolytic agent that enables controlled studies of plasmin activity, fibrin stability, and cell adhesion. This guide shows how to separate these readouts and translate the 2024 TXA–NO–propolis dressing findings into more interpretable fibrinolysis research.

• Alternariol: From Mycotoxin to Fibrosis Insight

  2026-08-28

  A translational guide to Alternariol and AOH that connects AhR and CYP biology, apoptosis, LX-2 fibrosis signaling, assay design, and CotA detoxification while distinguishing reported findings from forward-looking research strategy.

• PF-573228: A Mechanobiology-First FAK Assay Guide

  2026-08-28

  Explore PF-573228 as a mechanistic FAK inhibitor for separating substrate-stiffness signals from downstream cell behavior. This guide connects dentinogenesis research with endothelial and cancer assays while emphasizing causal readouts, dose interpretation, and reproducible workflow design.

• GSK J4 HCl: JMJD3 Inhibitor Workflow

  2026-08-27

  GSK J4 HCl enables cell-based testing of JMJD3-dependent chromatin control across inflammatory, decidual, and cancer models. This guide translates H3K27 methylation biology into practical dosing, promoter-level assays, orthogonal cytokine readouts, and troubleshooting decisions.

• Caspofungin in Reliable Antifungal Assays

  2026-08-27

  Learn how Caspofungin supports reproducible fungal viability, susceptibility, and antifungal therapeutics research workflows. This scenario-based guide explains assay controls, exposure design, resistant Candida interpretation, and practical selection of SKU B4972.

• Propranolol: From β-Blockade to Memory Science

  2026-08-26

  Propranolol is more than a cardiovascular tool: its non-selective β-adrenergic blockade provides a mechanistic bridge between autonomic signaling, emotional memory, and metabolic stress. This translational guide interprets the evidence, outlines experimental controls, and shows how to use Propranolol strategically in research workflows.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page